Androstene-3,5-dienes as ER-beta selective SERMs.
A series of androstene-3,5-diene derivatives were prepared. Despite lacking the C-3 hydroxyl previously believed necessary for ER activity, some of the analogs retained surprising affinity for ER-beta. For example, diene 4 retained excellent selectivity and potency as an ER-beta agonist and was more selective for ER-beta over the androgen receptor (AR).
Blizzard
Timothy A
TA
Merck Research Laboratories, Rahway, NJ 07065, USA. tim_blizzard@merck.com
Gude
Candido
C
Morgan
Jerry D
JD
Chan
Wanda
W
Birzin
Elizabeth T
ET
Mojena
Marina
M
Tudela
Consuelo
C
Chen
Fang
F
Knecht
Kristin
K
Su
Qin
Q
Kraker
Bryan
B
Mosley
Ralph T
RT
Holmes
Mark A
MA
Rohrer
Susan P
SP
Hammond
Milton L
ML
D000730:Androstadienes / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D018360:Crystallography, X-Ray; D047629:Estrogen Receptor beta / Q000819:agonists*; D006801:Humans; D020128:Inhibitory Concentration 50; D015394:Molecular Structure; D051381:Rats; D011944:Receptors, Androgen / Q000187:drug effects; D020845:Selective Estrogen Receptor Modulators / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*
D000730:Androstadienes; D047629:Estrogen Receptor beta; D011944:Receptors, Androgen; D020845:Selective Estrogen Receptor Modulators